Known in popular media as the ‘spirit molecule’ DMT is an acute acting psychedelic tryptamine that induces profound psychotropic effects through its actions on multiple serotonin receptor subtypes. Long used by South American indigenous groups as the primary psychoactive component in the shamanic brew Ayahuasca, research and translational studies directed at harnessing the potential of DMT for human illness have been limited in much of the world through acts of prohibition.

PharmaDrug Treads a New Path in its Development of DMT for Non-Neuropsychiatric Indications

DMT is produced naturally in the body and acts on serotonin receptor subtypes that are broadly expressed in many tissues, however the impact of DMT outside of its obvious psychotropic effects on the brain are little understood. PharmaDrug has formed an impressive working group of renowned academic researchers to investigate the underpinnings of how DMT impacts health and disease.

PharmaDrug’s Psychedelic
Commercial Strategy:
The Holy Trinity
  • • Unique indication
  • • Unique formulation
  • • Unique delivery technology
PharamDrug: Investing
in Basic Science

Partnered with the University of Michigan to study the role of endogenous DMT in the brain

PharamDrug: Investing in
Translational Science

Enters Into a Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study

PharamDrug: Breaking New
Ground in Non-Neuropsychiatric

Sponsored research agreement with the Terasaki Institute to develop a novel ocular drug delivery for DMT in eye diseases

Obtained orphan drug designation for DMT to treat ischemia-reperfusion injury in organ transplant patients

DMT For Glaucoma

Based on compelling 3rd party data examining the impact of serotonin
signalling in the eye, PharmaDrug is pursuing an R&D strategy for DMT
to treat glaucoma.

  • Glaucoma causes pathological increases in intraocular pressure (“IOP”) leading to vision loss
  • Existing treatments (typically eye drops) are only partially successful due side effects, poor compliance, and the increase in IOP overnight
  • Research has shown that elevated IOP can be reduced though activation of specific serotonin receptors
  • Tryptamine family members (of which DMT is one) have been shown to reduce IOP by activating 5HT-1a and 5HT-2a receptors
  • PharmaDrug is currently evaluating & developing novel formulations of DMT to address elevated IOP
  • Partnered with Terasaki Institute to develop a proprietary ocular delivery technology for DMT
PharmaDrug is Developing a Medical Device
to Deliver a Sub-Psychotropic, Ophthalmic
DMT Formulation (or Analogue) to Treat

The impact of serotonin receptor activation has been implicated in healthy regulation of
pressure in the eye. Increased pressure in the eye, a hallmark of glaucoma, results in
damage to the optic nerve and irreversible vision loss. PharmaDrug is using its deep
knowledge about DMT-driven activation of serotonin receptors in the eye to formulate
transformative medications to treat and prevent vision loss.

Get The Latest PharmaDrug